Comparative Pharmacology
Head-to-head clinical analysis: CLOXAPEN versus PENICILLIN G POTASSIUM IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLOXAPEN versus PENICILLIN G POTASSIUM IN PLASTIC CONTAINER.
CLOXAPEN vs PENICILLIN G POTASSIUM IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cloxapen inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBPs involved in the transpeptidation step of peptidoglycan cross-linking. It is resistant to staphylococcal beta-lactamases.
Penicillin G is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and activating autolytic enzymes.
Oral: 250-500 mg every 6 hours. IV: 1-2 g every 4-6 hours.
2-4 million units IV every 4 hours for moderate to severe infections; up to 24 million units/day for serious infections (meningitis, endocarditis).
None Documented
None Documented
Terminal elimination half-life 1.5-2 hours; prolonged to 2.5-4 hours in severe renal impairment; clinical context: requires frequent dosing in normal renal function
0.5–1 hour (normal renal function). Prolonged in renal impairment (up to 7–10 hours in anuria).
Renal 70-80% as unchanged drug and active metabolite; biliary 5-10%; fecal <5%
Renal: 60–90% unchanged via tubular secretion and glomerular filtration. Biliary/fecal: <10%.
Category C
Category A/B
Penicillin Antibiotic
Penicillin Antibiotic